Skip to main content
GutCited

락토바실루스 애시도필루스 관련 과민성 대장 증후군(IBS)

B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.

장 통과시간을 개선하고 IBS-C 증상을 줄입니다. 대변 pH가 감소해 발효 개선을 시사합니다. 락토바실루스 애시도필루스 NCFM 균주에 대한 근거가 가장 우수합니다.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Dacidophilus\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

결론

장 통과시간을 개선하고 IBS-C 증상을 줄입니다. 대변 pH가 감소해 발효 개선을 시사합니다. 락토바실루스 애시도필루스 NCFM 균주에 대한 근거가 가장 우수합니다.

Key Study Findings

Randomized Controlled Trial n=200 12 weeks Double-blind
Probiotic Blend of Lactobacillus acidophilus LA-5 and Bifidobacterium animalis ssp. Lactis BB-12 in Non-constipated Irritable …
Dose: None vs: placebo Outcome: IBS-Global Improvement Scale response 효과: 19.3% vs 8.9% response at day 28 p=0.048

대상 집단: adults with non-constipated irritable bowel syndrome

Meta-Analysis n=3154
Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable …
Dose: None vs: placebo Outcome: quality of life, depression, and anxiety in IBS … 효과: SUCRA=89.7% (B. longum for QoL); SUCRA=95.6% (probiotic combo for depression) None

대상 집단: patients with irritable bowel syndrome

Randomized Controlled Trial n=61 12 weeks Double-blind
Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel …
Dose: None vs: Placebo Outcome: IBS-SSS (100-point reduction) 효과: 45% active vs 33% placebo (P=0.42) P=0.42

대상 집단: IBD patients with IBS symptoms in remission

Randomized Controlled Trial 4 weeks
Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group …
Dose: 2 g vs: Placebo Outcome: Constipation symptoms 효과: None P = 0.005

대상 집단: IBS patients

Randomized Controlled Trial 12 weeks Double-blind
Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides …
Dose: None vs: Placebo Outcome: Quality of life 효과: None p = 0.023

대상 집단: IBS patients

Other
Computational prediction of new therapeutic effects of probiotics.
Dose: None vs: None Outcome: Colitis severity 효과: None None

대상 집단: Crohn's disease patients

Key Statistics

3

연구

350

참여자

↑

Positive

B

등급

Referenced Papers

Diseases (Basel, Switzerland) 2018 50 인용
Alimentary pharmacology & … 2010 4 인용
Neurogastroenterology and motility 2009 81 인용
Minerva gastroenterologica e … 2006 22 인용
Journal of clinical … 2004 298 인용
Journal of clinical … 2004 205 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

general:
1-10 billion CFU/day
ibssupport:
10 billion CFU/day for 4-8 weeks
lactosesupport:
1-2 billion CFU with dairy consumption

상한량: Generally well-tolerated up to 20 billion CFU/day

연구에서 사용된 용량

용량 기간 효과 N
None 12 weeks Positive 200
None -- Positive 3154
None 12 weeks Neutral 61
2 g 4 weeks Mixed --
None 12 weeks Positive --
None -- Neutral --
10^9 CFU L. acidophilus LA-5 + L. paracasei daily 12 weeks Positive 110
None -- Positive --

권장 복용 시간: On an empty stomach or before meals; may also be taken with dairy

Safety & Side Effects

보고된 부작용

  • ⚠ Mild gas and bloating during initial use
  • ⚠ Occasional loose stools
  • ⚠ Rare allergic reactions in dairy-sensitive individuals (dairy-cultured strains)
  • ⚠ Very rare: bacteremia in immunocompromised individuals

알려진 상호작용

  • ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • ● Immunosuppressants (theoretical risk in immunocompromised patients)
  • ● Sulfasalazine (may affect bacterial metabolism)

일일 최대 섭취 허용량: Generally well-tolerated up to 20 billion CFU/day

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does 락토바실루스 애시도필루스 help with 과민성 대장 증후군(IBS)?
Based on 3 studies with 350 participants, there is moderate evidence from clinical studies that 락토바실루스 애시도필루스 may support 과민성 대장 증후군(IBS) management. Our evidence grade is B (Good Evidence).
How much 락토바실루스 애시도필루스 should I take for 과민성 대장 증후군(IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 락토바실루스 애시도필루스?
Reported side effects may include Mild gas and bloating during initial use, Occasional loose stools, Rare allergic reactions in dairy-sensitive individuals (dairy-cultured strains), Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 락토바실루스 애시도필루스 and 과민성 대장 증후군(IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 350 total participants. The overall direction of effect is positive.

References

  1. [1] Uday C Ghoshal et al.. J Gastroenterol Hepatol. 2026. Probiotic Blend of Lactobacillus acidophilus LA-5 and Bifidobacterium animalis ssp. Lactis BB-12 in Non-constipated Irritable Bowel Syndrome: A Double-Blind Randomized … doi:10.1111/jgh.70137 PubMed
  2. [2] Theodore Rokkas et al.. Eur J Gastroenterol Hepatol. 2026. Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable bowel syndrome: a systematic review … doi:10.1097/MEG.0000000000003062 PubMed
  3. [3] Anne Fennessy et al.. World J Gastrointest Pharmacol Ther. 2025. Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel diseases in absence of inflammation … doi:10.4292/wjgpt.v16.i2.101268 PubMed
  4. [4] Marlynna Sarkawi et al.. Sci Rep. 2024. A randomized, double-blinded, placebo-controlled clinical trial on Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in irritable bowel syndrome. doi:10.1038/s41598-024-60029-2 PubMed
  5. [5] Sadegh Sulaimany et al.. Sci Rep. 2024. Computational prediction of new therapeutic effects of probiotics. doi:10.1038/s41598-024-62796-4 PubMed
  6. [6] Mattia Tinazzi et al.. Yale J Biol Med. 2024. Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal Extracts in an In Vitro … doi:10.59249/JOMF5336 PubMed
  7. [7] Anita Gąsiorowska et al.. J Clin Med. 2024. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel … doi:10.3390/jcm14010006 PubMed
  8. [8] Young Hoon Chang et al.. J Neurogastroenterol Motil. 2024. Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. doi:10.5056/jnm23036 PubMed
  9. [9] Lena Capirchio et al.. Int J Mol Sci. 2024. A Synbiotic Combining Chitin-Glucan and Lactobacillus acidophilus NCFM Induces a Colonic Molecular Signature Soothing Intestinal Pain and Inflammation in an … doi:10.3390/ijms251910732 PubMed
  10. [10] Peiwei Xie et al.. Nutrients. 2023. Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. doi:10.3390/nu15173856 PubMed
  11. [11] Arzu Hizay et al.. Anaerobe. 2023. Lactobacillus acidophilus regulates abnormal serotonin availability in experimental ulcerative colitis. doi:10.1016/j.anaerobe.2023.102710 PubMed
  12. [12] Ludovic D Langlois et al.. Int J Mol Sci. 2023. Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability in a Chronic-Restraint Stress Model. doi:10.3390/ijms24087220 PubMed
  13. [13] Veronica Cocetta et al.. Minerva Pediatr (Torino). 2023. Maintenance of intestinal epithelial barrier integrity by a combination of probiotics, herbal extract, and vitamins. doi:10.23736/S2724-5276.23.07128-8 PubMed
  14. [14] V N Drozdov et al.. Vopr Pitan. 2023. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea … doi:10.33029/0042-8833-2023-92-4-92-103 PubMed
  15. [15] Seung Yong Shin et al.. J Neurogastroenterol Motil. 2022. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: … doi:10.5056/jnm21202 PubMed
  16. [16] Cecilia Ceccherini et al.. Nutrients. 2022. Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review of Clinical Trials and Multi-Criteria Decision Analysis. doi:10.3390/nu14132689 PubMed
  17. [17] Jin Lee et al.. Gastroenterol Res Pract. 2022. Clinical Efficacy of Probiotic Therapy on Bowel-Related Symptoms in Patients with Ulcerative Colitis during Endoscopic Remission: An Observational Study. doi:10.1155/2022/9872230 PubMed
  18. [18] Luisa Marras et al.. Microorganisms. 2021. The Role of Bifidobacteria in Predictive and Preventive Medicine: A Focus on Eczema and Hypercholesterolemia. doi:10.3390/microorganisms9040836 PubMed
  19. [19] N Md Mokhtar et al.. Acta Gastroenterol Belg. 2021. Clinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink. doi:10.51821/84.4.009 PubMed
  20. [20] Christopher J Martoni et al.. Nutrients. 2020. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. doi:10.3390/nu12020363 PubMed
  21. [21] Barbara Skrzydło-Radomańska et al.. Nutrients. 2020. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant … doi:10.3390/nu12071999 PubMed
  22. [22] Stéphane Sadrin et al.. Dig Liver Dis. 2020. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. doi:10.1016/j.dld.2019.12.009 PubMed
  23. [23] Jean Michel Maixent et al.. Cell Mol Biol (Noisy-le-grand). 2020. Clinical effects of Lactobacillus strains as probiotics in the treatment of irritable bowel syndrome. Results from the LAPIBSS trial: Future … PubMed
  24. [24] Konstantinos Leventogiannis et al.. Probiotics Antimicrob Proteins. 2019. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. doi:10.1007/s12602-018-9401-3 PubMed
  25. [25] Ki-Bae Hong et al.. BMC Complement Altern Med. 2019. Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model. doi:10.1186/s12906-019-2610-9 PubMed
  26. [26] Mary Scriven et al.. Diseases. 2018. Neuropsychiatric Disorders: Influence of Gut Microbe to Brain Signalling. doi:10.3390/diseases6030078 PubMed
  27. [27] K Preston et al.. Benef Microbes. 2018. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. doi:10.3920/BM2017.0105 PubMed
  28. [28] Ya-Nan Cao et al.. Saudi J Gastroenterol. 2018. Lactobacillus acidophilus and Bifidobacterium longum supernatants upregulate the serotonin transporter expression in intestinal epithelial cells. doi:10.4103/sjg.SJG_333_17 PubMed
  29. [29] S Sadrin et al.. Cell Mol Biol (Noisy-le-grand). 2017. Lactobacillus acidophilus versus placebo in the symptomatic treatment of irritable bowel syndrome: the LAPIBSS randomized trial. doi:10.14715/cmb/2017.63.9.21 PubMed
  30. [30] Anna Lyra et al.. World J Gastroenterol. 2016. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. doi:10.3748/wjg.v22.i48.10631 PubMed
  31. [31] Bojana Bogovič Matijašić et al.. J Dairy Sci. 2016. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of … doi:10.3168/jds.2015-10743 PubMed
  32. [32] Hyuk Yoon et al.. J Clin Biochem Nutr. 2015. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a … doi:10.3164/jcbn.15-14 PubMed
  33. [33] Jun Sik Yoon et al.. J Gastroenterol Hepatol. 2014. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. doi:10.1111/jgh.12322 PubMed
  34. [34] János Fehér et al.. Orv Hetil. 2014. [Correlation of the microbiota and intestinal mucosa in the pathophysiology and treatment of irritable bowel, irritable eye, and irritable mind … doi:10.1556/OH.2014.29987 PubMed
  35. [35] María Ortiz-Lucas et al.. Rev Esp Enferm Dig. 2013. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. doi:10.4321/s1130-01082013000100005 PubMed
  36. [36] Luise Mølenberg Begtrup et al.. Scand J Gastroenterol. 2013. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. doi:10.3109/00365521.2013.825314 PubMed
  37. [37] Marina L Ritchie et al.. PLoS One. 2012. A meta-analysis of probiotic efficacy for gastrointestinal diseases. doi:10.1371/journal.pone.0034938 PubMed
  38. [38] Bong Ki Cha et al.. J Clin Gastroenterol. 2012. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, … doi:10.1097/MCG.0b013e31823712b1 PubMed
  39. [39] Javier Diaz Ferrer et al.. Rev Gastroenterol Peru. 2012. [Probiotic supplement (Lactobacillus acidophilus and bulgaricus) utility in the treatment of irritable bowel syndrome]. PubMed
  40. [40] Tamar Ringel-Kulka et al.. J Clin Gastroenterol. 2011. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional … doi:10.1097/MCG.0b013e31820ca4d6 PubMed
  41. [41] A C Ford. Aliment Pharmacol Ther. 2010. Probiotics in irritable bowel syndrome: underachievers or underpowered? doi:10.1111/j.1365-2036.2009.04223.x PubMed
  42. [42] L Ohman et al.. Neurogastroenterol Motil. 2009. B-cell activation in patients with irritable bowel syndrome (IBS). doi:10.1111/j.1365-2982.2009.01272.x PubMed
  43. [43] Kyoung Sup Hong et al.. Gut Liver. 2009. Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. doi:10.5009/gnl.2009.3.2.101 PubMed
  44. [44] Dong Hyun Sinn et al.. Dig Dis Sci. 2008. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. doi:10.1007/s10620-007-0196-4 PubMed
  45. [45] Eamonn M M Quigley. Curr Opin Pharmacol. 2008. Probiotics in functional gastrointestinal disorders: what are the facts? doi:10.1016/j.coph.2008.08.007 PubMed
  46. [46] Christel Rousseaux et al.. Nat Med. 2007. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. doi:10.1038/nm1521 PubMed
  47. [47] M Astegiano et al.. Minerva Gastroenterol Dietol. 2006. Treatment of irritable bowel syndrome. A case control experience. PubMed
  48. [48] Thomas J Borody et al.. J Clin Gastroenterol. 2004. Bacteriotherapy using fecal flora: toying with human motions. doi:10.1097/01.mcg.0000128988.13808.dc PubMed
  49. [49] Alfredo Saggioro. J Clin Gastroenterol. 2004. Probiotics in the treatment of irritable bowel syndrome. doi:10.1097/01.mcg.0000129271.98814.e2 PubMed
  50. [50] A D Newcomer et al.. Am J Clin Nutr. 1983. Response of patients with irritable bowel syndrome and lactase deficiency using unfermented acidophilus milk. doi:10.1093/ajcn/38.2.257 PubMed

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.